Zobrazeno 1 - 10
of 8 474
pro vyhledávání: '"enzalutamide"'
Autor:
Roberto Alva‐Ruiz, Ryan D. Watkins, Jennifer L. Tomlinson, Jennifer A. Yonkus, Amro M. Abdelrahman, Caitlin B. Conboy, Erik Jessen, Nathan W. Werneburg, Hendrien Kuipers, Jack W. Sample, Gregory J. Gores, Sumera I. Ilyas, Mark J. Truty, Rory L. Smoot
Publikováno v:
FEBS Open Bio, Vol 14, Iss 11, Pp 1873-1887 (2024)
Cholangiocarcinoma (CCA) is a highly aggressive form of liver cancer and is an increasing cause of cancer‐related death worldwide. Despite its increasing incidence globally and alarming mortality, treatment options for CCA have largely remained unc
Externí odkaz:
https://doaj.org/article/c06dce51bdf6443f86bb9d8ffcc1a4dc
Autor:
Shengfeng Zheng, Zhe Hong, Yao Tan, Yue Wang, Junhong Li, Zihao Zhang, Tao Feng, Zongyuan Hong, Guowen Lin, Dingwei Ye
Publikováno v:
Cell Communication and Signaling, Vol 22, Iss 1, Pp 1-18 (2024)
Abstract Background Enzalutamide (Enz) resistance is a poor prognostic factor for patients with castration-resistant prostate cancer (CRPC), which often involves aberrant expression of the androgen receptor (AR). Myosin VI (MYO6), one member of the m
Externí odkaz:
https://doaj.org/article/d1079f57180f4bbcadd7823b49752e59
Publikováno v:
Research and Reports in Urology, Vol Volume 16, Pp 245-252 (2024)
Alastair Thomson,1 Lucinda Gunn,1 Deborah Victor,1 Ellis Adamson,1 Kashyap Thakrar2 1Oncology Department, Sunrise Centre, Royal Cornwall Hospital, Truro, Cornwall, UK; 2Accord-UK Ltd, Barnstaple, Devon, UKCorrespondence: Alastair Thomson, Oncology de
Externí odkaz:
https://doaj.org/article/311f255081c046a49be8ae64f92c8689
Autor:
Jie Mu, Ruizhi Li, Yu Zheng, Yi Lu, Lei Ma, Lin Yin, Miao Zhang, Wenyu Ma, Mengjia Chang, Aihua Liu, Jing Li, Hai Zhu, Dong Wang
Publikováno v:
Stem Cell Research & Therapy, Vol 15, Iss 1, Pp 1-16 (2024)
Abstract Background Intermediate cells are present in the early stages of human prostate development and adenocarcinoma. While primary cells isolated from benign human prostate tissues or tumors exhibit an intermediate phenotype in vitro, they cannot
Externí odkaz:
https://doaj.org/article/91c6e2b653db426688625279c1c5c38c
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Prostate cancer is a malignant tumor caused by the malignant proliferation of epithelial cells, which is highly heterogeneous and drug-resistant, and neuroendocrine prostate cancer (NEPC) is an essential cause of drug resistance in its late stage. El
Externí odkaz:
https://doaj.org/article/9306f1e5a6ad4af896c3f9f41cb99ca8
Publikováno v:
European Journal of Medical Research, Vol 29, Iss 1, Pp 1-12 (2024)
Abstract Enzalutamide (Enz) is commonly utilized as the initial treatment strategy for advanced prostate cancer (PCa). However, a notable subset of patients may experience resistance to Enz, resulting in reduced effectiveness. Utilizing Gene Expressi
Externí odkaz:
https://doaj.org/article/3e16b3d5c1494ba1af6fc6ca187ee066
Autor:
K Ganesh Kadiyala, K. Jagadeesh, Ch. Geetika, I. Lakshmi Lavanya, B. Kanaka Durga, J. Suresh Kumar, Bachina Kiran, B. N. Suresh Varma Dendukuri
Publikováno v:
Proceedings on Engineering Sciences, Vol 6, Iss 3, Pp 1317-1326 (2024)
Molecular docking simulations were conducted to analyze the interactions between eight lead molecules with AR and PSA proteins. The lead molecules included Enzalutamide, Abiraterone, Docetaxel, Apalutamide, Cabazitaxel, Bicalutamide, Curcumin, Galete
Externí odkaz:
https://doaj.org/article/7cd3e08550d54968b81543b4dd43e5e9
Autor:
Fangyan Gao, Yueyao Wu, Runtian Wang, Yuhui Yao, Yiqiu Liu, Lingling Fan, Jingtong Xu, Jian Zhang, Xin Han, Xiaoxiang Guan
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 14, Iss 6, Pp 2685-2697 (2024)
Targeting androgen receptor (AR) has shown great therapeutic potential in triple-negative breast cancer (TNBC), yet its efficacy remains unsatisfactory. Here, we aimed to identify promising targeted agents that synergize with enzalutamide, a second-g
Externí odkaz:
https://doaj.org/article/45f66f1ea509476a91a29259b00bd1bf
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
Several life-prolonging therapies with diverse mechanisms of action (MoA) are available for the treatment of metastatic hormone-sensitive/castration-resistant prostate cancer, with many patients requiring multiple lines of therapy. Nevertheless, trea
Externí odkaz:
https://doaj.org/article/b9f8d3ab32f84af684fc3de8c23f1af9
Autor:
Syeda Afshan, Yu Gang Kim, Jesse Mattsson, Malin Åkerfelt, Pirkko Härkönen, Martin Baumgartner, Matthias Nees
Publikováno v:
Cancer Medicine, Vol 13, Iss 18, Pp n/a-n/a (2024)
Abstract Background Inhibition of androgen receptor (AR) signaling is the main treatment strategy in advanced prostate cancer (PCa). A subset of castration resistant prostate cancer (CRPC) bypasses the AR blockade by increased fibroblast growth facto
Externí odkaz:
https://doaj.org/article/50bad1de5a494228b47b0e9e0c70543a